OSTX Quote, Financials, Valuation and Earnings

Calidi Biotherapeutics has a net margin of -- compared to OS Therapies's net margin of --. OS Therapies's return on equity of -- beat Calidi Biotherapeutics's return on equity of --.

OS Therapies has a consensus price target of $13.50, signalling upside risk potential of 743.75%. On the other hand Calidi Biotherapeutics has an analysts' consensus of $6.25 which suggests that it could grow by 1194%. Given that Calidi Biotherapeutics has higher upside potential than OS Therapies, analysts believe Calidi Biotherapeutics is more attractive than OS Therapies.

OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Calidi Biotherapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Calidi Biotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. Calidi Biotherapeutics pays out -- of its earnings as a dividend.

OS Therapies quarterly revenues are --, which are smaller than Calidi Biotherapeutics quarterly revenues of --. OS Therapies's net income of -$2.9M is higher than Calidi Biotherapeutics's net income of -$5.1M. Notably, OS Therapies's price-to-earnings ratio is -- while Calidi Biotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus -- for Calidi Biotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of -- compared to OS Therapies's net margin of --. OS Therapies's return on equity of -- beat CEL-SCI's return on equity of --.

OS Therapies has a consensus price target of $13.50, signalling upside risk potential of 743.75%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 2654.82%. Given that CEL-SCI has higher upside potential than OS Therapies, analysts believe CEL-SCI is more attractive than OS Therapies.

OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.939%.

OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

OS Therapies quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. OS Therapies's net income of -$2.9M is higher than CEL-SCI's net income of -$7.1M. Notably, OS Therapies's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

Moleculin Biotech has a net margin of -- compared to OS Therapies's net margin of --. OS Therapies's return on equity of -- beat Moleculin Biotech's return on equity of --.

OS Therapies has a consensus price target of $13.50, signalling upside risk potential of 743.75%. On the other hand Moleculin Biotech has an analysts' consensus of $10.67 which suggests that it could grow by 906.29%. Given that Moleculin Biotech has higher upside potential than OS Therapies, analysts believe Moleculin Biotech is more attractive than OS Therapies.

OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moleculin Biotech has a beta of 2.195, suggesting its more volatile than the S&P 500 by 119.505%.

OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moleculin Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. Moleculin Biotech pays out -- of its earnings as a dividend.

OS Therapies quarterly revenues are --, which are smaller than Moleculin Biotech quarterly revenues of --. OS Therapies's net income of -$2.9M is lower than Moleculin Biotech's net income of -$1.9M. Notably, OS Therapies's price-to-earnings ratio is -- while Moleculin Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus -- for Moleculin Biotech. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services has a net margin of -- compared to OS Therapies's net margin of 12.87%. OS Therapies's return on equity of -- beat West Pharmaceutical Services's return on equity of 17.47%.

OS Therapies has a consensus price target of $13.50, signalling upside risk potential of 743.75%. On the other hand West Pharmaceutical Services has an analysts' consensus of $281.83 which suggests that it could grow by 31.36%. Given that OS Therapies has higher upside potential than West Pharmaceutical Services, analysts believe OS Therapies is more attractive than West Pharmaceutical Services.

OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison West Pharmaceutical Services has a beta of 1.221, suggesting its more volatile than the S&P 500 by 22.112%.

OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services offers a yield of 0.38% to investors and pays a quarterly dividend of $0.21 per share. OS Therapies pays -- of its earnings as a dividend. West Pharmaceutical Services pays out 12% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

OS Therapies quarterly revenues are --, which are smaller than West Pharmaceutical Services quarterly revenues of $698M. OS Therapies's net income of -$2.9M is lower than West Pharmaceutical Services's net income of $89.8M. Notably, OS Therapies's price-to-earnings ratio is -- while West Pharmaceutical Services's PE ratio is 33.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus 5.44x for West Pharmaceutical Services. Usually stocks with elevated PS ratios are considered overvalued.